KRAS Inhibitors Market is Set for Expansion During the Forecast Period (2026-2036) Supported by Emerging Therapies Targeting Diverse KRAS Mutations | DelveInsight

Summary

DelveInsight's market report projects strong growth in the KRAS inhibitors market from 2026 to 2036, driven by rising cancer incidence, improved treatment access, and a pipeline including divarasib, olomorasib, and MK-1084. The article is a market research promotion and contains no new clinical or regulatory data.